283 related articles for article (PubMed ID: 24956411)
1. Crystal structure of deglycosylated human IgG4-Fc.
Davies AM; Jefferis R; Sutton BJ
Mol Immunol; 2014 Nov; 62(1):46-53. PubMed ID: 24956411
[TBL] [Abstract][Full Text] [Related]
2. Room temperature structure of human IgG4-Fc from crystals analysed in situ.
Davies AM; Rispens T; Ooijevaar-de Heer P; Aalberse RC; Sutton BJ
Mol Immunol; 2017 Jan; 81():85-91. PubMed ID: 27915153
[TBL] [Abstract][Full Text] [Related]
3. Structural determinants of unique properties of human IgG4-Fc.
Davies AM; Rispens T; Ooijevaar-de Heer P; Gould HJ; Jefferis R; Aalberse RC; Sutton BJ
J Mol Biol; 2014 Feb; 426(3):630-44. PubMed ID: 24211234
[TBL] [Abstract][Full Text] [Related]
4. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
5. Structure of the murine unglycosylated IgG1 Fc fragment.
Feige MJ; Nath S; Catharino SR; Weinfurtner D; Steinbacher S; Buchner J
J Mol Biol; 2009 Aug; 391(3):599-608. PubMed ID: 19559712
[TBL] [Abstract][Full Text] [Related]
6. The Structural Role of Antibody N-Glycosylation in Receptor Interactions.
Subedi GP; Barb AW
Structure; 2015 Sep; 23(9):1573-1583. PubMed ID: 26211613
[TBL] [Abstract][Full Text] [Related]
7. Glycosylation of human IgG-Fc: influences on structure revealed by differential scanning micro-calorimetry.
Ghirlando R; Lund J; Goodall M; Jefferis R
Immunol Lett; 1999 May; 68(1):47-52. PubMed ID: 10397155
[TBL] [Abstract][Full Text] [Related]
8. Human IgG4: a structural perspective.
Davies AM; Sutton BJ
Immunol Rev; 2015 Nov; 268(1):139-59. PubMed ID: 26497518
[TBL] [Abstract][Full Text] [Related]
9. Revisiting the role of glycosylation in the structure of human IgG Fc.
Borrok MJ; Jung ST; Kang TH; Monzingo AF; Georgiou G
ACS Chem Biol; 2012 Sep; 7(9):1596-602. PubMed ID: 22747430
[TBL] [Abstract][Full Text] [Related]
10. Structural characterization of the Man5 glycoform of human IgG3 Fc.
Shah IS; Lovell S; Mehzabeen N; Battaile KP; Tolbert TJ
Mol Immunol; 2017 Dec; 92():28-37. PubMed ID: 29031045
[TBL] [Abstract][Full Text] [Related]
11. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity.
Krapp S; Mimura Y; Jefferis R; Huber R; Sondermann P
J Mol Biol; 2003 Jan; 325(5):979-89. PubMed ID: 12527303
[TBL] [Abstract][Full Text] [Related]
12. IgG2 Fc structure and the dynamic features of the IgG CH2-CH3 interface.
Teplyakov A; Zhao Y; Malia TJ; Obmolova G; Gilliland GL
Mol Immunol; 2013 Nov; 56(1-2):131-9. PubMed ID: 23628091
[TBL] [Abstract][Full Text] [Related]
13. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T
PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484
[TBL] [Abstract][Full Text] [Related]
14. Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions.
Schlothauer T; Herter S; Koller CF; Grau-Richards S; Steinhart V; Spick C; Kubbies M; Klein C; Umaña P; Mössner E
Protein Eng Des Sel; 2016 Oct; 29(10):457-466. PubMed ID: 27578889
[TBL] [Abstract][Full Text] [Related]
15. Carbohydrate and domain architecture of an immature antibody glycoform exhibiting enhanced effector functions.
Crispin M; Bowden TA; Coles CH; Harlos K; Aricescu AR; Harvey DJ; Stuart DI; Jones EY
J Mol Biol; 2009 Apr; 387(5):1061-6. PubMed ID: 19236877
[TBL] [Abstract][Full Text] [Related]
16. Structural differences between glycosylated, disulfide-linked heterodimeric Knob-into-Hole Fc fragment and its homodimeric Knob-Knob and Hole-Hole side products.
Kuglstatter A; Stihle M; Neumann C; Müller C; Schaefer W; Klein C; Benz J;
Protein Eng Des Sel; 2017 Sep; 30(9):649-656. PubMed ID: 28985438
[TBL] [Abstract][Full Text] [Related]
17. IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation.
Jefferis R; Lund J; Pound JD
Immunol Rev; 1998 Jun; 163():59-76. PubMed ID: 9700502
[TBL] [Abstract][Full Text] [Related]
18. Global conformational changes in IgG-Fc upon mutation of the FcRn-binding site are not associated with altered antibody-dependent effector functions.
Burvenich IJG; Farrugia W; Liu Z; Makris D; King D; Gloria B; Perani A; Allan LC; Scott AM; Ramsland PA
Biochem J; 2018 Jul; 475(13):2179-2190. PubMed ID: 29794155
[TBL] [Abstract][Full Text] [Related]
19. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose.
Ferrara C; Grau S; Jäger C; Sondermann P; Brünker P; Waldhauer I; Hennig M; Ruf A; Rufer AC; Stihle M; Umaña P; Benz J
Proc Natl Acad Sci U S A; 2011 Aug; 108(31):12669-74. PubMed ID: 21768335
[TBL] [Abstract][Full Text] [Related]
20. Recognition of IgG by Fcgamma receptor. The role of Fc glycosylation and the binding of peptide inhibitors.
Radaev S; Sun PD
J Biol Chem; 2001 May; 276(19):16478-83. PubMed ID: 11297533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
